BH3 주식 개요 바이오 제약 회사인 PTC 테라퓨틱스는 미국 및 전 세계 희귀 질환 환자를 위한 의약품의 발견, 개발 및 상용화에 주력하는 기업입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
PTC Therapeutics, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 PTC Therapeutics 과거 주가 현재 주가 US$42.80 52주 최고치 US$49.60 52주 최저치 US$22.00 베타 0.63 1개월 변경 -8.94% 3개월 변경 사항 31.29% 1년 변경 사항 69.84% 3년 변화 19.55% 5년 변화 -7.36% IPO 이후 변화 220.05%
최근 뉴스 및 업데이트
PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia Dec 19
An undisclosed buyer entered into an agreement to acquire Rare Pediatric Disease Priority Review Voucher of PTC Therapeutics, Inc. from PTC Therapeutics, Inc. (NasdaqGS:PTCT) for $150 million. Nov 29
PTC Therapeutics, Inc. Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients Nov 27
PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy Nov 14
New minor risk - Profitability Nov 11
New minor risk - Shareholder dilution Nov 10 더 많은 업데이트 보기
PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia Dec 19
An undisclosed buyer entered into an agreement to acquire Rare Pediatric Disease Priority Review Voucher of PTC Therapeutics, Inc. from PTC Therapeutics, Inc. (NasdaqGS:PTCT) for $150 million. Nov 29
PTC Therapeutics, Inc. Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients Nov 27
PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy Nov 14
New minor risk - Profitability Nov 11
New minor risk - Shareholder dilution Nov 10
Third quarter 2024 earnings released: US$1.39 loss per share (vs US$1.76 loss in 3Q 2023) Nov 08
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024 Nov 08
PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission Nov 02
PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination Oct 18
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results Oct 15
PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program Oct 08
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients Oct 02
New minor risk - Profitability Aug 09
Second quarter 2024 earnings released: US$1.29 loss per share (vs US$2.66 loss in 2Q 2023) Aug 09
PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda Jul 30
PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients Jun 20
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza May 15
PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 Apr 27
First quarter 2024 earnings released: US$1.20 loss per share (vs US$1.89 loss in 1Q 2023) Apr 26
PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024 Apr 12
New major risk - Share price stability Mar 29
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA Mar 28
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency Mar 20
Full year 2023 earnings released: US$8.37 loss per share (vs US$7.79 loss in FY 2022) Mar 01
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 Mar 01
PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 16
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure Jan 26
CEO & Director recently sold €250k worth of stock Jan 10
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024 Jan 08
PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities Dec 06
PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023 Oct 28
New major risk - Financial position Oct 27
PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Oct 25
New major risk - Financial position Sep 19
New minor risk - Profitability Aug 07
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 04
Second quarter 2023 earnings released: US$2.66 loss per share (vs US$2.13 loss in 2Q 2022) Aug 04
PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures Jun 30
Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients Jun 22
PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization May 25
PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023 May 24 PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria May 18
First quarter 2023 earnings released: US$1.89 loss per share (vs US$1.78 loss in 1Q 2022) Apr 30
CEO, COO & Director recently sold €57k worth of stock Apr 21
Forecast to breakeven in 2025 Feb 23
Full year 2022 earnings released: US$7.79 loss per share (vs US$7.44 loss in FY 2021) Feb 22
Co-Founder recently sold €110k worth of stock Feb 05
Co-Founder recently sold €80k worth of stock Jan 13
PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023 Jan 10
PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors Dec 07
PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil Dec 02
Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™ Nov 18
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.89 loss in 3Q 2021) Oct 28 PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.
PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518 Oct 19
Insider recently sold €116k worth of stock Aug 13
PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates Aug 06
Second quarter 2022 earnings released: US$2.13 loss per share (vs US$1.68 loss in 2Q 2021) Aug 05 PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2022
PTC Therapeutics, Inc. Announces Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency Jul 21
PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors Jun 10
PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study Jun 04
PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old May 31
PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency May 21
First quarter 2022 earnings released: US$1.78 loss per share (vs US$1.83 loss in 1Q 2021) May 05
PTC Therapeutics, Inc. Provides Earnings Guidance for 2022 May 05
Insufficient new directors Apr 27
PTC Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 20
PTC Therapeutics, Inc. Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program Apr 15
PTC Therapeutics, Inc. Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease Mar 31
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
PTC Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2022 Feb 24
Co-Founder recently sold €80k worth of stock Feb 07
PTC Therapeutics, Inc. Announces FDA Grants Evrysdi® Priority Review Based on Results from Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy Jan 25
Co-Founder recently sold €73k worth of stock Jan 13
PTC Therapeutics, Inc. Reports Earnings Guidance for the Year 2021 and 2022 Jan 12
Insufficient new directors Jan 02
Forecast to breakeven in 2024 Jan 01
Oral Splicing Modifiers Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform Dec 21
Third quarter 2021 earnings released: US$1.89 loss per share (vs US$1.03 loss in 3Q 2020) Oct 29
PTC Therapeutics, Inc. Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome Aug 24
Insider recently sold €56k worth of stock Aug 18
Second quarter 2021 earnings released: US$1.68 loss per share (vs US$2.79 loss in 2Q 2020) Jul 31
PTC Therapeutics, Inc. Announces Results of Evidence Confirming Emflaza®'s Benefit over Prednisone Jun 25
PTC Therapeutics, Inc. Announces Evrysdi™ Approval in Japan for the Treatment of Spinal Muscular Atrophy Jun 24
Ptc Therapeutics, Inc. Announces Pre-Symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in Rainbowfish Jun 11
PTC Therapeutics, Inc. Announces Data from the First Study on the Impact of Caring for Child with the Ultra-Rare Genetic Disorder, Aromatic L-Amino Acid Decarboxylase Deficiency May 18
First quarter 2021 earnings released: US$1.83 loss per share (vs US$1.81 loss in 1Q 2020) May 06
PTC Therapeutics, Inc. Reaffirms Earnings Guidance for Full Year 2021 May 05 주주 수익률 BH3 DE Biotechs DE 마켓 7D -3.2% 2.3% 0.3% 1Y 69.8% -14.0% 6.9%
전체 주주 수익률 보기
수익률 대 산업: BH3 지난 1년 동안 -14 %를 반환한 German Biotechs 산업을 초과했습니다.
수익률 대 시장: BH3 지난 1년 동안 6.9 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is BH3's price volatile compared to industry and market? BH3 volatility BH3 Average Weekly Movement 10.0% Biotechs Industry Average Movement 7.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: BH3 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: BH3 의 주간 변동성 ( 10% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 바이오 제약 회사인 PTC 테라퓨틱스는 미국 및 전 세계 희귀 질환 환자를 위한 의약품의 발견, 개발 및 상용화에 주력하고 있습니다. 회사는 듀센 근이영양증 치료제인 트랜라나와 엠플라자, 중추신경계 질환인 방향족 L-아미노산 데카르복실라 결핍증 치료제인 업스타자, 희귀질환 치료제인 테그세디와 웨이리브라, 성인 및 소아 척수성 근위축증(SMA) 치료제인 에브리스디를 공급하고 있습니다. 개발 파이프라인 제품으로는 페닐케톤뇨증 치료제 세피아페린, 헌팅턴병 치료를 위해 개발 중인 PTC518 스플라이싱 플랫폼, 프리드리히 운동실조증 치료제 바티퀴논과 근위축성 측삭경화증 치료제 우트렐록사스타트를 포함한 페로프증 및 염증 플랫폼이 있습니다.
자세히 보기 PTC Therapeutics, Inc. 기본 사항 요약 PTC Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? BH3 기본 통계 시가총액 €3.36b 수익(TTM ) -€437.47m 수익(TTM ) €869.41m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) BH3 손익 계산서(TTM ) 수익 US$900.66m 수익 비용 US$601.30m 총 이익 US$299.37m 기타 비용 US$752.57m 수익 -US$453.20m
주당 순이익(EPS) -5.88 총 마진 33.24% 순이익 마진 -50.32% 부채/자본 비율 -224.5%
BH3 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/01 08:03 장 마감 주가 2024/12/30 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 PTC Therapeutics, Inc. 27 애널리스트 중 14 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Joel Beatty Baird Huidong Wang Barclays Geoffrey Meacham Barclays
24 더 많은 분석가 보기 
